Roche Igea Luca Dezzani

1 September 2016

Roche has announced positive results for TECENTRIQ® from the Phase III study, which met its co-primary endpoints and revealed a clinically meaningful and statistically significant improvement in overall survival (OS) compared with docetaxel chemotherapy in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease progressed on or after treatment with platinum-based chemotherapy. It was also showed that adverse events were consistent with what has been previously observed for TECENTRIQ. Roche is looking forward to presenting full results at an upcoming medical meeting.

Sandra Horning, MD, Chief Medical Officer and Head of Global Product Development, Roche, said: “These results add to the growing body of evidence that supports the role of TECENTRIQ as a potential new treatment for specific types of advanced NSCLC. This is very encouraging news for people living with this disease because lung cancer is the leading cause of cancer deaths around the world. We hope to bring this treatment option to patients as soon as possible.”

Eight Phase III lung studies of Roche is underway that evaluate TECENTRIQ alone or in combination with other treatments in patients with early and advanced stages of lung cancer.

2 thoughts on “Roche’s cancer immunotherapy TECENTRIQ (atezolizumab) assisted people with a particular type of lung cancer live significantly longer compared to chemotherapy, Phase III study showed

Leave a Reply